In an effort to better understand the policy and access environment in Europe for people living with Spinal Muscular Atrophy (SMA), SMA Europe and Biogen, in collaboration with Charles River Associates, have developed the White Paper ‘Assessing the policy and access environment across European countries for SMA patients’ and the accompanying ‘SMA Policy & Access Tracker’. These offer a comparative assessment of the status of SMA access and policy across 23 European countries and put forward policy recommendations to improve access to care for people living with SMA in Europe.

With this interactive multi-stakeholder virtual roundtable, SMA Europe and Biogen presented their work and bring light to the challenges faced by people living with SMA. The event brought together national and EU-level stakeholders with an interest in SMA and neuromuscular rare diseases and provide a platform to analyse issues surrounding SMA care in Europe.

The event offered a unique opportunity to hear more about the policy and access environment across 23 European countries for people living with SMA, to learn about best practices and gaps in SMA care and to gain a greater understanding of how to tackle these with clear policy actions.

THE EVENT WAS ORGANISED BY: SMA Europe and Biogen

MEDIA PARTNER: EURACTIV